The focus of the Children's Vaccine Initiative is to encourage the discovery of technology that will make vaccines more readily available to developing countries. Our strategy has been to genetically engineer plants so that they can be used as inexpensive alternatives to fermentation systems for production of subunit antigens. In this paper we report on the immunological response elicited in vivo by using recombinant hepatitis B surface antigen (rHBsAg) purified from transgenic tobacco leaves. The anti-hepatitis B response to the tobacco-derived rHBsAg was qualitatively similar to that obtained by immunizing mice with yeast-derived rHBsAg (commercial vaccine). Additionally, T cells obtained from mice primed with the tobacco-derived rHBsAg could be stimulated in vitro by the tobacco-derived rHBsAg, yeast-derived rHBsAg, and by a synthetic peptide that represents part of the a determinant located in the S region (139-147) of HBsAg. Further support for the integrity of the T-cell epitope of the tobacco-derived rHBsAg was obtained by testing the ability of the primed T cells to proliferate in vitro after stimulation with a monoclonal anti-idiotype and an anti-idiotype-derived peptide, both of which mimic the group-specific a determinant of HBsAg. In total, we have conclusively demonstrated that both B-and T-cell epitopes of HBsAg are preserved when the antigen is expressed in a transgenic plant.
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On a global basis, hepatitis B virus (HBV) infection is probably the single most important cause of persistent viremia in humans. Current estimates establish that there are '300 million carriers of HBV in the world. Continued transmission of HBV is thus assured by the existence of this large reservoir of persistent human carriers (1) . The worldwide problem of HBV infection and its association with chronic liver disease has necessitated the development of an effective vaccine. Because HBV cannot be propagated in tissue culture and the host range is limited to chimpanzees and humans, the first vaccine consisted of hepatitis B surface antigen (HBsAg) purified from the plasma of HBsAg carriers (2) . However, concerns about the safety of serum-derived HBsAg resulted in the development of the first commercially available recombinant vaccine, produced by expression of HBsAg in yeast. Intramuscular injections of serum-derived HBsAg or yeast-derived recombinant HBsAg (rHBsAg) in healthy individuals result in effective immunization and protection from viral infection (2) .
In many areas of the developing world the expense of immunization programs prohibits the use of the currently available vaccines for large segments of the population. This limitation led us to attempt the expression of HBsAg in plants with the hope of developing a product that is less expensive to produce and that would not require a cold chain during distribution.
The first step in demonstrating concept feasibility for plantbased vaccine production came when we reported that the gene encoding HBsAg can be expressed in tobacco plants. The tobacco-derived rHBsAg self-assembles into subviral particles, which are virtually indistinguishable from serum-derived HBsAg and yeast-derived rHBsAg with respect to size, density sedimentation, and antibody binding (3) . From these data we concluded that plants can produce an immunologically reactive antigen from an animal virus.
Here we report on the immunogenic properties of tobaccoderived rHBsAg and show that it can elicit HBsAg-specific antibodies in BALB/c mice and prime T cells in vivo that can be stimulated in vitro by the yeast-derived rHBsAg used in current vaccines.
MATERIALS AND METHODS
Preparation of rHBsAg from Tobacco. Transgenic plants expressing rHBsAg were grown from tobacco (Nicotiana tabacum cv. Samsun) seed harvested from plants that had been transformed by Agrobacterium infection as described (3) . Leaves (200-300 g) were homogenized in a blender with liquid nitrogen, and the resulting powder was extracted overnight at 4°C in buffer (1 ml/g fresh wt) containing 0.1 M sodium phosphate (pH 7.4), 0.1 M sodium ascorbate, 0.1% Triton X-100, and 2 mM phenylmethylsulfonyl fluoride. The extract was centrifuged 30 min at 30,000 x g and additionally for 40 min at 40,000 x g. The resulting supernatant was concentrated by ultrafiltration with a YM30 membrane (Amicon) to 20-30 ml and frozen at -20°C.
Upon thawing, the sample was centrifuged for 10 min at 12,000 x g, and the supernatant was loaded onto 10-40% sucrose gradients, and these were centrifuged at 100,000 x g for 13-14 hr. 
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Isotype Distribution of Anti-HBsAg Responses. An analysis of the isotype distribution of the anti-HBsAg response showed that mice immunized with the tobacco-derived rHBsAg produced HBsAg-specific antibody of all the IgG subclasses and also IgM antibodies (Table 1 tValues represent the average of sera from two mice bled 3, 4, and 5
weeks after the third injection.
of antibodies is also the most efficient at activating the complement pathway. Mouse T-Cell Stimulation. To examine the fidelity of the T-cell epitope expressed by the tobacco-derived rHBsAg, we examined the in vitro proliferative response of mouse lymphnode T cells. BALB/c mice were primed in vivo with the tobacco-derived rHBsAg, and the primed T cells were tested for their ability to proliferate in vitro to appropriate stimuli. Table 2 shows that T cells from mice primed in vivo with the tobacco-derived rHBsAg can be recalled in vitro to proliferate upon stimulation with not only the immunizing antigen (tobacco-derived rHBsAg) but also to yeast-derived rHBsAg and to a synthetic 9-aa peptide designated as the HBsAg peptide (CTKPTDGNC; ref. 4) , which represents a partial analogue of the group-specific a determinant located in the S region (139-147) of HBsAg. This result is significant in that it indicates that the tobacco-derived rHBsAg had primed T cells in vivo that are crossreactive in vitro with the commercially used yeast-derived rHBsAg and that the reactivity is directed to the peptide sequence that is a part of the protective a determinant (S139-147) of HBsAg.
Proliferation of T cells was also elicited by a monoclonal anti-idiotype 2F10, and a linear 15-mer synthetic peptide was derived from the anti-idiotype sequence. We had previously shown (5) that monoclonal antibody 2F10 is an internal image anti-idiotype that mimics the group-specific a determinant of HBsAg. We had also demonstrated that immunization with this anti-idiotype can elicit HBsAg-specific antibodies and T cells in several mouse strains (4). Further, we had identified a 15-aa sequence (AVYYCTRGYHGSSLY) in the heavy-chain hypervariable region of this anti-idiotype that has partial residue homology with sequences of the a determinant epitopes of HBsAg (6) . A 15-aa synthetic peptide corresponding to this area of homology can generate anti-HBsAg-specific antibodies when injected into mice and prime murine lymph node cells for an in vitro HBsAg-specific T-cell proliferative response (6) . Thus, the ability of the anti-idiotype 2F10 and the 2F10 peptide to stimulate in vitro proliferation of T cells (Table 2) obtained (9) . Because our previous studies had shown that tobacco leaf cells can express rHBsAg (3), we were interested in examining the immunological characteristics of this material and comparing it with yeast-derived rHBsAg, which is the current source of commercially available HBV vaccine. The results presented here conclusively show that rHBsAg from transgenic tobacco elicits HBsAg-specific B-and T-cell responses in mice; hence both the B-and T-cell epitopes are preserved in the plant-derived material. The development of an antiHBsAg-specific antibody response to the tobacco-derived rHBsAg was qualitatively similar to that seen after immunization with the yeast-derived rHBsAg. Although the response to the tobacco-derived rHBsAg was of a slightly lower magnitude, the tobacco preparation used for immunization was relatively impure, with the rHBsAg representing <3% of the total protein in the sample in comparison with the highly purified yeast antigen. The ability of such an impure preparation to produce the antibody responses observed in this study is particularly significant because foreign antigens expressed in edible plant tissues for use as oral vaccines also will consist of impure mixtures with numerous other plant proteins.
The ability of the tobacco-derived rHBsAg to prime T cells for a subsequent HBsAg-specific T-cell proliferative response to in vitro stimulation (Table 2 ) with yeast-derived rHBsAg indicated that the T-cell epitopes of both antigens are similar. More importantly, the primed T cells were also stimulated by a 9-aa synthetic HBsAg peptide that represents a partial sequence of the group-specific a determinant located in the S region (139-147) of HBsAg. The integrity of the T-cell epitope was also tested by using another set of reagents-namely, an internal image anti-idiotype (2F10) that mimics the groupspecific a determinant of HBsAg and a 15-aa synthetic peptide (2F10 peptide; ref. 6 Proc. Natl. Acad Sci. USA 92 (1995) retains the immunological properties needed to elicit HBsAgspecific B-and T-cell responses.
In our studies of antigen production in plants thus far, we have used tobacco as the initial test system. This approach has allowed analysis of gene expression in comparison with an extensive literature that has developed around this facile tool for molecular biologists. Unfortunately, tobacco tissues are rich in toxic alkaloids that prevent direct animal feeding studies. Now that it is obvious that there are no inherent limitations to the expression or aggregation of rHBsAg in tobacco cells and that the protein expressed is immunologically active, we have developed transformation systems for other plant species. For example, by using a patatin promoter that drives tuber-specific protein expression (10), we have achieved expression levels of rHBsAg in potato tubers comparable with those in tobacco leaves. Because we anticipate that accumulation levels of any foreign protein in plant cells may be limited when the polypeptide simply accumulates in the cell cytoplasm, studies must be directed to the construction of transformation vectors that contain DNA sequences that target polypeptides to specific cellular compartments. Furthermore, expression levels in edible plant tissues must be maximized so that oral immunogenicity of HBsAg in untreated edible plant tissues can be evaluated.
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